BSECompany Update16 Oct 2026 · 16 Oct 2026, 03:15 pm
Conversion of Warrants into Equity Shares
Shelter Pharma Ltd · 543963
✦ AI SummaryResults
Shelter Pharma Ltd has converted 465,000 warrants into 465,000 equity shares, increasing its paid-up equity share capital from Rs. 168,367,920 to Rs. 173,017,920. The conversion was done at an issue price of Rs. 42.25 per share, with the remaining exercise price of Rs. 31.6875 per share warrant being paid in cash.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk2/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Shelter Pharma Ltd - 543963 - Announcement under Regulation 30 (LODR)-Allotment
Attachments (1)
📄pdf
Download →
4d39dcc1-52b6-4925-98c3-0c3ef32d138a.pdf
View document text
The Manager,
Department of Corporate Services,
BSE Limited,
Phirozee Jeejeeboy Towers,
Dalal Street, Fort,
Mumbai - 400 001.
Scrip Code: 543963
Dear Sir/Madam,
Subject: Outcome of the Board Meeting held on Friday, October 16, 2026.
This is in continuation to our earlier disclosure dated 06th August, 2025 wherein we had
informed that in furtherance to approval of the Shareholders granted at the 01/2025-26 Extra
Ordinary General Meeting of the Members held on Wednesday, July 23rd , 2025 and further
pursuant to the In-principle approval accorded by BSE Limited (“BSE”) vide their letter ref:
LOD/PREF/AM/FIP/572/2025-26 dated 22nd July, 2025, the Company had allotted in
aggregate 88,08,000 (Eighty Eight Lakhs and Eight Thousand) Convertible Equity Warrants
(“Warrants”) of face value of ₹ 10/- (Rupees Ten Only) each at an issue price of ₹ 42.25/-
(Rupees Forty-Two and Twenty-Five Paise Only) each of the Company, on receipt of Warrants
Subscription money @ 25% of the issue price.
In this regard, we wish to inform you that in terms of issue of said Warrants, some of the
Warrants Holders (Belonging to Promoters) as listed below in Annexure–I, have exercised
their option of conversion of warrants and Pursuant to the Regulation 30 of the Securities and
Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
("SEBI Listing Regulations"), we hereby inform you that the Board of Directors of the
Company at its Meeting held today i.e. October 16, 2026 have inter alia, considered and
approved the conversion of 465000 warrants into 465000 equity shares of face value of
Rs. 10/- (Rupees Ten Only) each out of the warrants allotted by way of preferential allotment
to the persons (as detailed in Annexure I) pursuant to exercise of their right of conversion of
warrants into equity shares and accordingly the Board of Directors have allotted 465000
equity shares of face value of Rs.10/- each, fully paid, up on account of conversion.
The allotment has been made for cash, upon the receipt of the remaining exercise price of Rs.
31.6875/- per share warrant [being an amount equivalent to the 75% of the warrant issue price,
i.e. Rs. 42.25/- per warrant (including premium of Rs. 32.25/- per warrant)], aggregating to
Rs. 14,734,687.50 /-.
The equity shares allotted on the preferential allotment basis shall rank pari-passu with the
existing equity shares of the Company in all respects.
Consequent to the aforesaid conversion the paid-up equity share capital of the Company has
increased from Rs. 168367920/- consisting of 16836792 equity shares of Face Value Rs. 10/-
each to Rs. 173017920/- consisting of 17301792 equity shares of Face Value Rs. 10/- each.
The application for listing and trading approval of the Stock Exchange for the newly issued
and allotted Equity Shares will be made in due course of time.
Further, the information required under the Regulation 30 of the SEBI (Listing Obligations
and Disclosure Regulations, 2015 read with SEBI No. SEBI/HO/CFD/PoD2/CIR/P/0155
dated November 11, 2024, are enclosed to this letter as Annexure II.
Kindly note that the meeting of the Board of Directors commenced at 02:30 P.M. and
concluded at 03:00 P.M.
The above information is also being made available on the website of the Company at
www.shelter.co.in.
You are requested to take the above information on record.
Thanking you,
Yours faithfully,
For Shelter Pharma Limited
Mustaqim Nisarahmed Sabugar
Managing Director
DIN: 01456841
Date: 16th October, 2026
Place: Ahmedabad
Encl: as above
ANNEXURE –I
Sr. Investor Name Category No of Warrants Shares Total Amount Balance
No Warrants Already allotted upon Paid for Outstanding
Alloted Converted conversion of Conversion Warrants
warrants on (In Rs.) for
16th October, conversion
2026
1 Mustaqim Promoter 750,000 285,000 NIL
Nisarahmed
Sabugar 465,000 14,734,687.50
Total 465000 14,734,687.50 NIL
ANNEXURE - II
Disclosures as required under Regulation 30 of the SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015
Sr. Particulars Details
1. Types of securities proposed to Equity shares allotted pursuant to conversion of
be Issued fully paid warrants.
2. Type of issuance (further public Preferential Allotment (on conversion of warrants
offering, rights issue, into equity shares) in accordance with the SEBI
depository receipts (ICDR) Regulation 2018 read with the Companies
(ADR/GDR), qualified Act, 2013 and rules made thereunder.
institutions placement,
preferential allotment etc.)
3. Total number of Allotment of equity shares at an Issue price of Rs.
Securities proposed to be issued 42.25/-each (including premium of Rs. 32.25/- per
or the total amount for which share), on receipt of the balance amount at the rate
the securities will be issued of Rs. 31.6875/- against each Warrant (being 75%
of Issue Price)
Additional details
i. Names of the investors As per Annexure I
ii. No. of Investors 1
In case of convertibles - Exercise of conversion option of 465000 warrants
intimation on conversion of into 465000 fully paid up equity shares.
securities or on lapse of the
tenure of the instrument
5 Any cancellation or termination Not Applicable
of proposal for issuance of
securities including reasons
thereof